Aosikang biological sprint scientific innovation board of Hillhouse Investment: annual revenue of 450million yuan, lost cooperation with kangxinuo

RedI network Lei Jianping 7 month 5 Reported Wednesday

Auscon biology （ nantong ） limited company （ abbreviation ：“ Auscon biology ”） The prospectus was submitted a few days ago , Ready to be listed on the science and technology innovation board . Auscon biological project fundraising 30 One hundred million yuan .

among ,5.5 Billion yuan is used for the R & D and production project of Shanghai aosikang coupling drug ,14.5 Billion yuan for Shanghai aosikang biopharmaceutical CDMO Platform project ,10 Billion yuan is used to supplement working capital .

Annual revenue 4.5 Billion Lose the cooperation with conchino

Aosikang biology is based on biological drugs CMC At the forefront of , With their own integrity 、 flexible 、 The modular production process platform cooperates closely with domestic and foreign institutions , Quickly improve their innovation ability , at present CDMO The sector has served dozens of customers , The cell culture medium plate exceeds 200 Multiple customers .

Aosikang biology in the medium formula 、 Process development services 、CDMO Service cooperation , It has established agency or strategic cooperative relations with Asian multinational enterprises , The company is also looking for more strategic partners .

The prospectus shows , Auscon biology 2019 year 、2020 year 、2021 The annual revenue is 8713.6 Ten thousand yuan 、2.1 One hundred million yuan 、4.51 One hundred million yuan ; The net profit is respectively -7975 Ten thousand yuan 、-3817 Ten thousand yuan 、7186.86 Ten thousand yuan ; The net profit after deducting non profits is -8613 Ten thousand yuan 、-4773.5 Ten thousand yuan 、4641 Ten thousand yuan .

At the end of each reporting period , The book value of the company's accounts receivable is 2906.69 Ten thousand yuan 、8193.97 Million and $ 1.6 One hundred million yuan , The proportions in the total assets are 8.61%、11.16% and 5.04%.

2022 year 1 month 13 Japan , Due to the regulatory policy adjustment of vaccine production , Kangxinuo terminated the contract for the commissioned production of adenovirus covid-19 vaccine stock solution from auscon Biology （ Auscon biology others CDMO Business is not affected ）,2022 year 1 month 28 Japan , In the production scope of the aosikang biopharmaceutical production license, the entrusted production of recombinant novel coronavirus vaccine has been reduced （5 Adenovirus vector ） Relevant contents of stock solution .

After the termination of the entrusted production business of adenovirus covid-19 vaccine stock solution between auscon biology and kangxinuo , Aosikang biology has adjusted its production schedule in time , Switch the production capacity originally used for the commissioned production of coxinuo covid-19 vaccine stock solution to other customer projects , But the switching process requires cleaning of the production line 、 Equipment commissioning and other work , And the production of new projects should follow the capacity climbing process of gradually increasing the operating load .

Hillhouse and Fosun are shareholders

Auscon biology 2019 In, it was announced to complete the super 3 One hundred million yuan A Round of funding ;2020 year 7 month , Announced a complete 4.5 One hundred million yuan B Round of funding ;2021 year 3 month , Announce the completion of super 4 One hundred million yuan C Round of funding , This round of financing is funded by China's state-owned capital venture capital fund （ abbreviation “ National Venture Capital Fund ”） Jointly lead the investment with Hillhouse venture capital , CDH investment 、 Honghui capital 、 China US Green Fund 、 Sany innovation fund and many other new investment institutions and Jinshi investment 、 CICC capital 、 Fosun's fund and other old shareholders jointly contributed .

2021 year 12 month , Auscon announced the completion 15 A new round of financing of 100 million yuan , Led by shareholders Jinshi investment and CDH Baifu , Many well-known institutions follow the investment .

IPO front ,SHUN LUO Yuanyuan biological indirect control through personal shareholding platform 18.07% Shares of , Through the employee stock ownership platform, Chengmai Jianshun 、 Auscon one indirectly controls the company 7.01%、0.85% Shares of , Total controlling company 25.93% Shares of .

SHUN LUO, In Chinese, “ Luoshun ”.1962 year 7 born , American nationality , Permanent residency in China , Graduated from Virginia Tech University , Doctor of molecular immunology .1993 year 8 Month to 1999 year 9 month , He was appointed as the chief researcher of Swiss cerano biopharmaceutical Co., Ltd ;1999 year 9 Month to 2001 year 8 month , ren Beckman Coulter,Inc. Chief scientist ;2001 year 8 Month to 2003 year 2 month , ren Gene XP Biosciences Chairman of the board of directors ;2003 year 2 Month to 2005 year 9 month , ren JRH Biosciences R & D director of R & D department ;

SHUN LUO2005 year 11 Month to 2008 year 2 month , Ren us Genentech Inc. Scientific and technological director of cell culture technology research and Development Department ;2008 year 3 Month to 2011 year 6 month , Serve as the scientific and technological director of the cell culture process research and Development Department of Anjin company ;2011 year 7 Month to 2014 year 7 month , Serve as the CEO of Gansu Wanzhou Jianshun Biotechnology Co., Ltd ;2014 year 7 Month so far , Serve as chairman and general manager of Gansu Jianshun ;2017 year 3 Month so far , Serve as chairman and general manager of aosikang Biology .

Besides , CICC Jiatai holds 8.27%, Chengmai Jianshun holds 7.01%, Changxia Jinshi holds 5.68%, Shanghai Lianyi holds 4.82%, Hillhouse qianheng holds 4.21%, The shareholding of new materials fund is 2.3%, CCB international holds 2.29%, Shenzhen Yilong holds 2.27%, Guangdong Wen's shareholding is 2.25%, Guofeng Dingjia holds 2.16%;

Shixin biology holds 2.03%, Couplet health holdings is 1.95%,OLM The shareholding is 1.87%, Dry melt win run 、 Binghong harvest holds shares of 1.81%, CDH Junyao holds 1.72%, Fosun is only real 、 Fosun Weiying holds shares of 1.44%, Huaxu investment holds 1.34%, Jiaxing Lianyi holds 1.21%, Ren Jun Tianrun 、 Chen Xi No. 8 holds shares of 1.15%.

IPO after , The actual controller of the company is still SHUN LUO, but SHUN LUO The proportion of controlling shares in the company will be reduced to 19.45%.

Yuanyuan biological holdings is 13.55%, CICC Jiatai holds 6.2%, Chengmai Jianshun holds 5.25%, Changxia Jinshi holds 4.26%, Shanghai Lianyi holds 3.62%, Hillhouse qianheng holds 3.16%;

New materials Fund 、 CCB international holds 1.72%, Shenzhen Yilong holds 1.7%, Guangdong Wen's shareholding is 1.69%, Guofeng Dingjia holds 1.62%, Shixin biology holds 1.52%, Couplet health holdings is 1.46%, CDH Junyao holds 1.29%.

Fosun is only real 、 Fosun Weiying holds shares of 1.08%, Huaxu investment holds 1%, Jiaxing Lianyi holds 0.9%, Ren Jun Tianrun 、 Chen Xi No. 8 holds shares of 0.86%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .